Genentech: Cary Austin | Principal Scientist, Pathology

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/cary-austin

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"At Genentech, we strive to address unmet medical needs through innovative scientific discovery and tireless focus on translating discovery to medicines that help patients in need. I feel fortunate to be contributing to this important effort and to be collaborating with some of the best and brightest minds in science and medicine."

Years at Genentech

Publications

Awards & Honors

I completed a combined MD-PhD program at Albert Einstein College of Medicine in 1998 and an Anatomic Pathology Residency and Autopsy Fellowship at Stanford University Hospital in 2001. During my last year at Stanford, I began a postdoctoral fellowship in the laboratory of Richard H. Scheller and in 2001, moved with the laboratory to Genentech, where I investigated endocytosis and intracellular trafficking of cell surface receptors targeted by cancer therapeutics and armed antibodies. I completed the fellowship in 2005 and joined the Department of Pathology at Genentech, where I have since been providing collaborative pathology support for a variety of pipeline research and development programs and academic-focused projects in basic science, mostly in the areas of Immunology and Infectious Diseases.

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.

Toxicol Sci. 2016 Jul;152(1):72-84.

Rajapaksa KS, Huang T, Sharma N, Lui S, Solon M, Reyes A, Paul S, Yee A, Tao J, Chalasani S, Bien-Ly N, Barck K, Carano RD, Wang J, Rangell L, Bremer M, Danilenko DM, Katavolos P, Hotzel K, Reif K, Austin CD.

View Abstract

As a research pathologist, I use a combination of cutting edge molecular labeling and imaging technologies, in addition to more traditional tissue histology, to formulate and address tissue-based scientific questions contributing to the discovery and evaluation of new therapeutic targets, therapies designed specifically to those targets, and tissue biomarkers developed to predict therapeutic efficacy and/or monitor pharmacodynamic activity of the therapy. I’ve work collaboratively on many project teams over the years ranging from early discovery research through to late stage clinical trials. My focus is on allergic, inflammatory, and infectious diseases, with particular interest in asthma and systemic lupus nephritis.

Unstable mechanisms of resistance to inhibitors of escherichia coli lipoprotein signal peptidase

mBio, ISSN: 21612129

Homer Pantua; Elizabeth Skippington; Marie-Gabrielle Braun; Cameron Noland; Jingyu Diao; Yutian Peng; Susan Gloor; Donghong Yan; Jing Kang; Anand Kumar Katakam; Janina Reeder; Georgette Castanedo; Keira Garland; László Kömüves; Meredith Sagolla; Cary Austin; Jeremy Murray; Yiming Xu; Zora Modrusan; Min Xu; Emily Hanan; Sharookh Kapadia

The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells

Science Signaling, ISSN: 19379145

Alex Corzo; Eugene Varfolomeev; Francesca Setiadi; Ross Francis; Sha Klabunde; Kate Senger; Swathi Sujatha-Bhaskar; Joy Drobnick; Steven Do; Eric Suto; Zhiyu Huang; Jeff Eastham; Arna Katewa; Jodie Pang; Melanie Domeyer; Chris Dela Cruz; Andres Paler Martinez; Vivian W. C. Lau; Azadeh Hadadianpour; Vladimir Ramirez-Carrozi; Yonglian Sun; Katherine Bao; Daqi Xu; Emily Hunley; Hans Brightbill; Soren Warming; Meron Roose-Girma; Alfred Wong; Lucinda Tam; Claire Emson; James Crawford; Wendy Young; Rajita Pappu; Brent McKenzie; Vida Asghari; Domagoj Vucic; Jason Hackney; Cary Austin; Wyne Lee; Annemarie Lekkerkerker; Nico Ghilardi; Callie Bryan; James Kiefer; Michael Townsend; Ali Zarrin

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Cary Austin

Principal Scientist, Pathology

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.